Back to Peptides
PerformanceMedium Risk

IGF-1 LR3

Also known as: Insulin-like Growth Factor 1 Long R3, Long R3 IGF-1, IGF1 LR3, Long-R3-IGF-1

Half-life:
20–30 hours

Administration Routes

subcutaneousintramuscular
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1 LR3 is a synthetic, long-acting analog of insulin-like growth factor 1 used in research and clinical contexts for its potent anabolic and recovery-promoting effects. It stimulates muscle protein synthesis, supports fat metabolism, and may enhance recovery from injury. For educational purposes only — consult a qualified healthcare provider.

Primary Research Areas

  • muscle growth
  • recovery
  • fat metabolism
  • performance

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Modified IGF-1 analog (N-terminal extension + Arg3) with extended half-life. Distinct from approved mecasermin (Increlex). Not FDA-approved. WADA prohibited. Research chemical only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find IGF-1 LR3